Acrivon Therapeutics, Inc. (ACRV)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | 977.7k | -- | 1963 |
| Ms. Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director | 739.78k | -- | 1981 |
| Ms. Mary-Alice Miller J.D. | Chief Legal Officer | 587.11k | -- | 1974 |
| Mr. Rasmus Holm-Jorgensen | Chief Financial Officer | 1M | -- | 1972 |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer | 614.78k | -- | 1979 |
| Ms. Katharine Peterson CPA | Vice President of Finance & Accounting | -- | -- | -- |
| Dr. Adam D. Levy M.B.A., Ph.D. | Senior VP and Head of Investor Relations & Corporate Affairs | -- | -- | -- |
| Mr. Bruce Close | Vice President of Quality & Compliance | -- | -- | -- |
| Ms. Parvin Miah | VP & Head of Human Resources | -- | -- | -- |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer | 480.72k | -- | 1958 |
Acrivon Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 58
Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available